CRL monthly performance report
Monthly CRL research: returns, drawdown, relative strength, seasonality, and key stats.
CRL monthly report
—
Key takeaways
- Charles River Laboratories (CRL) closed September 2026 at $280.76, down 2.60% for the month and +73.31% over the trailing 12 months.
- Year-to-date, CRL is +40.75%, outperforming the S&P 500 which has returned +12.32% YTD.
- The stock is trading +40.79% versus its 200-day moving average ($199.41), a bullish technical signal.
- Over the past three years, CRL has underperformed the S&P 500 by −31.36%, with a relative strength index reading of 81.8.
- Win rate over the trailing 39 months stands at 43.6% — 17 positive months versus 22 negative months.
Charles River Laboratories ended September 2026 at $280.76, posting a monthly return of −2.60%. The S&P 500 returned −0.14% over the same window, leaving relative performance at −2.45%.
The current quarter stands at +23.80% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +40.79% versus the 200-day moving average ($199.41).
Year-to-date, CRL is +40.75% against SPY +12.32%, a gap of +28.42%. The stock is currently −7.43% below its 52-week high, with maximum 3-year drawdown at −63.52%.
| Period | CRL | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −2.68% | −0.55% | −2.13% |
| 1 Week | −5.28% | −0.44% | −4.84% |
| 1 Month | −2.60% | −0.14% | −2.45% |
| 3 Months | +56.09% | +1.17% | +54.92% |
| 6 Months | +59.80% | +11.80% | +48.01% |
| YTD | +40.75% | +12.32% | +28.42% |
| 12 Months | +73.31% | +18.05% | +55.26% |
| 3 Years | +40.56% | +71.92% | −31.36% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +25.50% |
| #2 | Aug 2026 | +23.97% |
| #3 | Dec 2023 | +19.95% |
| #4 | Jul 2024 | +18.16% |
| #5 | Feb 2024 | +17.53% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2025 | −21.19% |
| #2 | Aug 2024 | −18.99% |
| #3 | Apr 2024 | −15.48% |
| #4 | Feb 2026 | −15.20% |
| #5 | Oct 2023 | −14.09% |
| Quarter | Return |
|---|---|
| Q2 2025 | +0.80% |
| Q3 2025 | +3.12% |
| Q4 2025 | +27.50% |
| Q1 2026 | −13.53% |
| Q2 2026 | +31.47% |
| Q3 2026 (QTD) | +23.80% |
| Year | Return |
|---|---|
| 2023 | +8.49% |
| 2024 | −21.91% |
| 2025 | +8.06% |
| 2026 | +40.75% |
| Metric | Value |
|---|---|
| 52-Week High | $303.31 (2026-08-27) |
| 52-Week Low | $144.26 (2025-09-25) |
| Current Price | $280.76 |
| 200-Day Moving Average | $199.41 |
| Price vs 200DMA | +40.79% |
| 3-Year Maximum Drawdown | −63.52% (2025-04-11) |
| Current Drawdown from 52W High | −7.43% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 81.8 |
| 3-Year Excess Return vs S&P 500 | −31.36% |
| RS Peak | 117.1 (Mar 2024) |
| RS Trough | 41.7 (Apr 2025) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was CRL's return for this report period?
CRL returned −2.60% in the latest monthly window ending 2026-09-08.
Has CRL outperformed SPY year to date?
YTD CRL: +40.75% vs SPY: +12.32%.
What is CRL's 12-month return?
+73.31% over the trailing 12 months.
Is CRL above or below its 200-day moving average?
Price is +40.79% versus 200DMA ($199.41).
What is the maximum drawdown in the 3-year window?
−63.52% on 2025-04-11.